ZA921416B - Pharmaceutical compositions comprising interleukin-2 - Google Patents
Pharmaceutical compositions comprising interleukin-2Info
- Publication number
- ZA921416B ZA921416B ZA921416A ZA921416A ZA921416B ZA 921416 B ZA921416 B ZA 921416B ZA 921416 A ZA921416 A ZA 921416A ZA 921416 A ZA921416 A ZA 921416A ZA 921416 B ZA921416 B ZA 921416B
- Authority
- ZA
- South Africa
- Prior art keywords
- interleukin
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL97365A IL97365A0 (en) | 1991-02-27 | 1991-02-27 | Pharmaceutical compositions comprising a lymphokine |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA921416B true ZA921416B (en) | 1993-01-27 |
Family
ID=11062144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA921416A ZA921416B (en) | 1991-02-27 | 1992-02-26 | Pharmaceutical compositions comprising interleukin-2 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0501445A1 (xx) |
JP (1) | JPH05238941A (xx) |
KR (1) | KR920016106A (xx) |
AU (1) | AU647883B2 (xx) |
CA (1) | CA2061918A1 (xx) |
FI (1) | FI920845A (xx) |
HU (2) | HUT66231A (xx) |
IE (1) | IE920594A1 (xx) |
IL (1) | IL97365A0 (xx) |
MY (1) | MY131097A (xx) |
NZ (1) | NZ241719A (xx) |
TW (1) | TW208657B (xx) |
ZA (1) | ZA921416B (xx) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994003059A1 (en) * | 1992-07-30 | 1994-02-17 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Enzymatically-produced dimeric il-2 and a nerve-derived transglutaminase enzyme for its preparation |
US5800812A (en) * | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
ES2201287T5 (es) | 1996-03-22 | 2007-10-16 | Curis, Inc. | Metodo para mejorar la recuperacion funcional de la coordinacion motora, del habla o la percepcion sensorial tras una isquemia o trauma del sistema nervioso central. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4832686A (en) * | 1986-06-24 | 1989-05-23 | Anderson Mark E | Method for administering interleukin-2 |
IL91459A0 (en) * | 1989-08-28 | 1990-04-29 | Yeda Res & Dev | Oligodendrocyte inhibitory factor |
-
1991
- 1991-02-27 IL IL97365A patent/IL97365A0/xx unknown
-
1992
- 1992-02-25 IE IE059492A patent/IE920594A1/en not_active Application Discontinuation
- 1992-02-25 NZ NZ241719A patent/NZ241719A/en unknown
- 1992-02-26 CA CA002061918A patent/CA2061918A1/en not_active Abandoned
- 1992-02-26 FI FI920845A patent/FI920845A/fi not_active Application Discontinuation
- 1992-02-26 HU HU9303167A patent/HUT66231A/hu unknown
- 1992-02-26 AU AU11267/92A patent/AU647883B2/en not_active Ceased
- 1992-02-26 HU HU9200644A patent/HUT60437A/hu unknown
- 1992-02-26 EP EP92103260A patent/EP0501445A1/en not_active Withdrawn
- 1992-02-26 ZA ZA921416A patent/ZA921416B/xx unknown
- 1992-02-27 KR KR1019920003089A patent/KR920016106A/ko not_active Application Discontinuation
- 1992-02-27 MY MYPI92000322A patent/MY131097A/en unknown
- 1992-02-27 JP JP4090398A patent/JPH05238941A/ja active Pending
- 1992-04-13 TW TW081102862A patent/TW208657B/zh active
Also Published As
Publication number | Publication date |
---|---|
CA2061918A1 (en) | 1992-08-28 |
FI920845A0 (fi) | 1992-02-26 |
HUT60437A (en) | 1992-09-28 |
IL97365A0 (en) | 1992-05-25 |
NZ241719A (en) | 1994-12-22 |
HU9200644D0 (en) | 1992-05-28 |
KR920016106A (ko) | 1992-09-24 |
MY131097A (en) | 2007-07-31 |
HUT66231A (en) | 1994-10-28 |
IE920594A1 (en) | 1992-09-09 |
AU1126792A (en) | 1992-09-03 |
AU647883B2 (en) | 1994-03-31 |
FI920845A (fi) | 1992-08-28 |
TW208657B (xx) | 1993-07-01 |
HU9303167D0 (en) | 1994-01-28 |
JPH05238941A (ja) | 1993-09-17 |
EP0501445A1 (en) | 1992-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU9303143D0 (en) | Pharmaceutical compositions | |
ZA922834B (en) | Pharmaceutical compositions | |
GB9203084D0 (en) | Pharmaceutical composition | |
GB9108080D0 (en) | Pharmaceutical composition | |
GB9200253D0 (en) | Pharmaceutical compositions | |
GB9214757D0 (en) | Pharmaceutical compositions | |
ZA921416B (en) | Pharmaceutical compositions comprising interleukin-2 | |
GB9120672D0 (en) | Pharmaceutical compositions | |
GB9121631D0 (en) | Pharmaceutical compositions | |
GB2252497B (en) | Pharmaceutical composition | |
GB9200414D0 (en) | Pharmaceutical compositions | |
GB9111477D0 (en) | Pharmaceutical composition | |
GB9118128D0 (en) | Pharmaceutical compositions | |
GB9121989D0 (en) | Pharmaceutical compositions | |
GB9123423D0 (en) | Pharmaceutical compositions | |
GB9126766D0 (en) | Pharmaceutical compositions | |
GB9107278D0 (en) | Pharmaceutical compositions | |
GB9108643D0 (en) | Pharmaceutical compositions | |
GB9121291D0 (en) | Pharmaceutical compositions | |
GB9119048D0 (en) | Pharmaceutical compositions | |
GB9109452D0 (en) | Pharmaceutical compositions | |
GB9110884D0 (en) | Pharmaceutical compositions | |
GB9118481D0 (en) | Pharmaceutical compositions | |
GB9113805D0 (en) | Pharmaceutical compositions | |
GB9113621D0 (en) | Pharmaceutical compositions |